⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15963900 | 0.89 | — | — | |
| SCHEMBL12070410 | 0.81 | — | — | |
| SCHEMBL21426929 | 0.75 | — | — | |
| SCHEMBL24031644 | 0.75 | — | — | |
| SCHEMBL23220574 | 0.72 | — | — | |
| SCHEMBL17795542 | 0.69 | — | — | |
| SCHEMBL19079897 | 0.69 | — | — | |
| SCHEMBL14087030 | 0.68 | — | — | |
| SCHEMBL10404 | 0.68 | — | — | |
| SCHEMBL5904396 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023239710-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023088441-A1 | KIF18A INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022090481-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2021226517-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2016086169-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2118082-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008045564-A2 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |